Publications by authors named "J M Liegel"
Despite increasing utilization of CAR T-cell therapy, data are lacking regarding long term follow up and risk of infectious complications after the early period following CAR T-cell infusion. In this study, we sought to compare epidemiology and risk factors for early (≤ 3 months) and late (3 months to 1 year) infections. Data were retrospectively collected at six time points: pre-CAR T, day of infusion, and at 3, 6, 9, and 12 months post CAR-T infusion for all consecutive adult patients treated at our institution.
View Article and Find Full Text PDFArticle Synopsis
- Dasatinib is a treatment for Philadelphia chromosome-positive (Ph+) acute leukemia, but some patients develop resistance, leading to the exploration of combining it with asciminib, an allosteric inhibitor to enhance efficacy.
- In a phase 1 study involving 24 adults, researchers aimed to determine the maximum tolerated dose of asciminib when used alongside dasatinib and prednisone for Ph+ acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) in lymphoid blast crisis.
- Results showed that the combination led to high rates of complete hematologic and cytogenetic remission, with the recommended dose of asciminib being 80 mg daily, while also demonstrating safety and minimal severe side effects.
Article Synopsis
- * Results indicated no significant differences in neutrophil engraftment, mortality, relapse rates, or overall survival between patients receiving high and standard doses of CD34+ cells.
- * The findings suggest that using higher CD34+ doses does not lead to increased graft-versus-host disease (GVHD) and do not provide justification for routinely reducing graft CD34+ doses.
Steroid-refractory chronic graft-versus-host disease (cGVHD) after allogeneic transplant remains a significant cause of morbidity and mortality. Abatacept is a selective costimulation modulator, used for the treatment of rheumatologic diseases, and was recently the first drug to be approved by the US Food and Drug Administration for the prophylaxis of acute graft-versus-host disease. We conducted a phase 2 study to evaluate the efficacy of abatacept in steroid-refractory cGVHD.
View Article and Find Full Text PDF